Short-term reductions in agitation were helpful, but other components of delirium need further study.
Nearly all terminally ill patients experience episodes of delirium, usually with agitation and restlessness, and they often are treated with haloperidol. When haloperidol is insufficient, some clinicians add a benzodiazepine (e.g., lorazepam), but others are reluctant to do so because of reported side effects. In this trial conducted in an acute palliative care unit at Houston's MD Anderson Cancer Center, 90 advanced-cancer patients (all with histories of agitated delirium), received intravenous (IV) haloperidol (2 mg every 4 hours; plus 2 mg additional, hourly as needed); if haloperidol failed to control agitation, patients were randomized to receive either IV lorazepam (3 mg) or placebo. All patients were treated for reversible causes of …
Reviewing Author
DisclosuresEditorial BoardsUpToDate
DisclosuresEditorial BoardsUpToDate